Clinical Report: Evaluating the Discontinuation of Tamsulosin in Elderly Males
Overview
This study investigates the efficacy of tamsulosin compared to placebo in older men with chronic lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH).
Background
Lower urinary tract symptoms (LUTS) are prevalent in older men, significantly impacting their quality of life and contributing to various adverse health outcomes. Tamsulosin, an α-1 adrenergic receptor antagonist, is commonly prescribed for LUTS associated with BPH.
Data Highlights
No numerical data or trial data presented in the source material.
Key Findings
One in three men with LUTS may not benefit from continued tamsulosin therapy.
The study utilized a double-blind, placebo-controlled N-of-1 trial design to assess individual responses to tamsulosin.
Participants underwent a 12-week trial with daily symptom assessments during treatment periods.
36.7% of participants experienced minimal or no effect from tamsulosin compared to placebo.
Individualized N-of-1 approaches can effectively quantify the benefits and harms of chronic tamsulosin therapy.
Clinical Implications
Clinicians should assess the necessity of continued tamsulosin therapy in older men on chronic treatment.
Conclusion
The study indicates that a substantial number of older men may be candidates for deprescribing tamsulosin, emphasizing the importance of personalized treatment strategies in managing LUTS.
by Scott R. Bauer, Stacey A. Kenfield, Akinyemi Oni-Orisan, Michael G. Shlipak, Kaiwei Lu, Natalie Rios, Robert Pearce, Joseph Harmon, Charles E. McCulloch, Liusheng Huang, Michael A. Steinman, Benjamin N. Breyer
A DOJ settlement resolved allegations involving a cash-pay pain practice in which continued access to controlled-substance prescriptions was tied to recurring payments.
